Ensysce Biosciences, Inc.
ENSC
$0.25
$0.00-1.11%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.07M | 4.49M | 7.41M | 6.22M | 5.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.07M | 4.49M | 7.41M | 6.22M | 5.21M |
| Cost of Revenue | 10.38M | 10.57M | 9.30M | 8.33M | 7.22M |
| Gross Profit | -5.31M | -6.08M | -1.89M | -2.10M | -2.01M |
| SG&A Expenses | 4.93M | 4.96M | 4.76M | 4.75M | 4.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.31M | 15.52M | 14.06M | 13.08M | 11.94M |
| Operating Income | -10.24M | -11.04M | -6.65M | -6.85M | -6.73M |
| Income Before Tax | -10.18M | -10.97M | -6.58M | -6.82M | -7.99M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.18 | -10.97 | -6.58 | -6.82 | -7.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 500.00 | 200.00 | 200.00 | 0.00 | 100.00 |
| Net Income | -10.18M | -10.97M | -6.58M | -6.82M | -7.99M |
| EBIT | -10.24M | -11.04M | -6.65M | -6.85M | -6.73M |
| EBITDA | -2.78M | -- | -- | -- | -- |
| EPS Basic | -4.22 | -6.37 | -4.07 | -6.63 | -13.45 |
| Normalized Basic EPS | -2.64 | -3.98 | -2.55 | -4.15 | -8.41 |
| EPS Diluted | -4.22 | -6.37 | -4.07 | -6.63 | -13.45 |
| Normalized Diluted EPS | -2.64 | -3.98 | -2.55 | -4.15 | -8.41 |
| Average Basic Shares Outstanding | 10.18M | 7.72M | 5.49M | 3.88M | 2.86M |
| Average Diluted Shares Outstanding | 10.18M | 7.72M | 5.49M | 3.88M | 2.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |